Floatz Rating
B57/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02311998CT.gov Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | — | Completed | — | — | — |
NCT00759837CT.gov Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bosutinib (this asset) | M.D. Anderson Cancer Center | P1/2 | B · 57 |
| Cyclophosphamide | City of Hope Medical Center | P3 | BBB |
| Nilotinib | Novartis Pharmaceuticals | P4 | BBB |
| Therapeutic Allogeneic Lymphocytes | University of Chicago | P2 | BBB |
| Romidepsin | Center for International Blood and Marrow Transplant Research | P2 | BBB |
| Sargramostim | Virginia Commonwealth University | P2 | BBB |
| Imatinib | OHSU Knight Cancer Institute | P2 | BB |
| Alemtuzumab | Diane George | P2/3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
+42 more in the Chronic Myeloid Leukemia cohort
Other indications for Bosutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glioblastoma | — | P2 | B · 59 |
| Lewy Body Dementia | — | P2 | CCC · 55 |
| Neoplasm | — | P1 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bosutinib in Chronic Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bosutinib-chronic-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →